The GHS 2018 Scientific Program Committee invites the submission of abstracts on original work. Abstracts can be submitted for consideration for an oral or poster presentation. All successful abstracts will be published on the GHS 2018 website. Presenting authors must be registrants at the Symposium. All abstracts must be submitted online via the Symposium website using the online submission form between March 1 and March 30.

Abstract Key Dates

Late-Breaking Abstract Submissions Open: March 1, 2018
Late-Breaking Abstract Submissions Close: March 30, 2018



All notifications for regular abstract submission has been sent to the email address provided during the time of submission. Should you not have received the notification, please check your spam folder or contact us at GHS2018-info@mci-group.com


A) Basic Science

a. Viral Hepatitis

i. Hepatitis B
ii. Hepatitis C
iii. Other Hepatitis Viruses

b. Animal and Tissue Culture Models
c. Fibrogenesis and Inflammation

B) Clinical 

a. Viral Hepatitis

i. Hepatitis B

1. Treatment
2. Pathogenesis & Natural History

ii. Hepatitis C

1. Treatment
2. Pathogenesis & Natural History

iii. Other Hepatitis Viruses

b. NAFLD, Fibrosis
c. Other

C) Public Health

a. Diagnostics & Epidemiology

i. Hepatitis B
ii. Hepatitis C

b. Outreach and Linkage to Care

c. Prevention and Vaccines 



Authors are invited to submit abstracts, classified by topics.
Submitted abstracts will be reviewed by the Local Organising Committee and chosen for oral presentations of 10-15 minutes.


Authors are invited to present their new research findings or important ongoing research as posters related to one of the given abstract topics on the next panel.

Abstract Submission Guidelines

Abstracts must be submitted via the website.

The Congress secretariat is not able to accept abstracts submitted via email or fax.

When submitting your abstract please follow the instructions listed on the website and take into account the following:

  • Abstracts may be submitted for Oral or Poster Presentations.
  • Abstract text should be a maximum of 2,500 characters or approximately 350 words (the word count does not include the title, the author, the affiliation and up to 1 table/figure).
  • Abstracts must be submitted in English.
  • The first letters of major words in the title should be capitalized.
  • 1 diagram, table or figure will be accepted as part of your abstract.
  • The use of standard abbreviations is required. Examples include kg, g, mg, ml, L (liter), meq, m (meter), mmol/L (millimoles per liter), and % (percent). Abbreviated terms should be expanded at first mention with the abbreviation in parentheses. Then the abbreviation used throughout the rest of the submission. Use numerals to indicate numbers, except when beginning sentences.
  • Non-proprietary (generic) names should be used the first time a drug is mentioned and typed in lowercase letters; trade names are always capitalized, for example, aspirin (Bufferin).
  • All abstracts and proposals must be submitted in blinded format. Identifiers such as city, province, or institution name should not be included within title or body of abstract or proposal.
  • The presenting author is required to ensure that all coauthors are aware of the content of the abstract before submission to the Secretariat.
  • Presenting authors of abstracts must be registered participants.
  • Authors with multiple abstracts should list their names the same way on all.
  • Abstracts must be received by the announced deadline. Abstracts received after the deadline will not be considered.
  • All notifications regarding the abstract status (including notification regarding acceptance) and scheduling will be sent to the presenting author(s).




Congress Secretariat
MCI Group Canada
18 Keewatin Avenue
Toronto, ON  M4P 1Z8
Email: GHS2018-info@mci-group.com
Tel: +1 416 621 2727

Info subject to change without notice.